Kornimate/medical-research-clean huggingface dataset:
real-world effectiveness and cardiovascular safety study of abaloparatide in postmenopausal women

Conditions: Osteoporosis, Postmenopausal

Summary: the purpose of the study is to evaluate the real-world effectiveness and cardiovascular safety of abl compared with tptd during the 18-month period after treatment initiation in propensity score (ps)-matched cohorts

this is a retrospective observational cohort study using healthcare administrative claims data from the usa. this study will use anonymized patient claims data from pra's symphony health patient source integrated dataverse (idv) database including the enhanced hospital data. data are routinely collected in healthcare encounters from all available healthcare sites (inpatient hospital, outpatient hospital, physician office, pharmacy, etc.) for all types of provided services including specialty, preventive care, and office-based treatments. the patients for inclusion in the study analyses will be identified based on the prescribed anabolic therapy filled (abl or tptd). the identification period (may 1, 2017 to june 30, 2019) was chosen to coincide with the date of the fda approval of abl in the usa.

Eligibility criteria:
inclusion criteria: * women who are 50 years or older * ≥1 prescription fill for abl or tptd during the identification period * ≥ 1 claim for medical or hospital visit and a pharmacy claim in the 12 months before the index date exclusion criteria: * paget's disease * malignancy, except for nonmelanoma skin cancers, carcinoma in-situ of the cervix, ductal carcinoma in-situ of breast * indicators of high disease burden and high risk of death * with prior index anabolic treatment * switch to a different anabolic treatment after index date
simulation of perinatal grief. (spg)

Conditions: Perinatal Death; Perinatal Grief; Teaching Innovation

Summary: a proposal for teaching innovation is proposed with the topic of "perinatal grief" very little studied and taught in degrees such as medicine, nursing and psychology, with scientific evidence demonstrating a knowledge deficit on the part of healthcare professionals.

a proposal for teaching innovation is proposed with the topic of "perinatal grief" very little studied and taught in degrees such as medicine, nursing and psychology, with scientific evidence demonstrating a knowledge deficit on the part of healthcare professionals. with the aim of improving this knowledge and the communication skills of the students who are taught, the objective is to introduce perinatal grief so that the level of knowledge on this topic increases and also increases their communication abilities in this aspect, being a very difficult topic to cover if you do not have training. to carry out teaching innovation, it is proposed, in addition to a master class to impart theoretical knowledge, to innovate by carrying out clinical simulation among students and through a questionnaire to evaluate whether this type of technique is effective for the acquisition of knowledge, skills to provide support. , improve self-awareness and also assess student satisfaction.

Eligibility criteria:
inclusion criteria: the sample population will be nursing students. specifically, the project will be proposed and offered to students who have taken the subject "women's care" in the third year. - exclusion criteria: those students who did not come to class the day that the activity took place, were excluded. -

Keywords: perinatal death grief teaching innovation clinical simulation
investigation of the effectiveness of whatsapp-based physical activity incentive program in morbidly obese individuals

Conditions: Physical Inactivity; Obesity, Morbid

Summary: the limited number of studies on the effectiveness of physical activity incentive programs for morbidly obese individuals in the literature shows the need in this area. in this study, primary aim is to investigate the effect of physical activity incentive program applied through face-to-face and whatsapp-based applications on physical activity level, functional capacity and muscular endurance in morbidly obese individuals. secondary aim is to provide individuals with exercise habits and to ensure participants' sustainability with the physical activity incentive program planned in line with the needs of the individual.


Eligibility criteria:
inclusion criteria: * individuals between the ages of 18-60 * bmi ≥40 kg/m2, morbidly obese awaiting bariatric surgery * no surgical operation in the last 6 months exclusion criteria: * having a musculoskeletal disorder or systemic disease that will interfere with physical activity * presence of balance problems that will prevent physical activity * presence of psychiatric or neurological disease affecting cooperation and cognitive functions * presence of acute pain * heartache * having a history of myocardial infarction * presence of conjunctive heart failure * presence of uncontrolled diabetes and hypertension

Keywords: physical activity morbid obesity exercise technology
ziv-aflibercept efficacy in better regulating amd

Conditions: Wet Macular Degeneration; Wet Age-related Macular Degeneration

Summary: this is a randomized, open-label, interventional, controlled study to determine the effects of zaltrap on neovascularized wet macular degeneration as compared to the control anti-vascular endothelial growth factor ("anti-vegf") injections (bevacizumab, ranibizumab, or aflibercept).


Eligibility criteria:
inclusion criteria: * are age 50-99 * have neovascular age-related macular degeneration ("amd") with an eye undergoing maintenance treatment with one or more of the following anti-vegf drugs: bevacizumab, ranibizumab, or aflibercept. * have an eye undergoing treatment that is of low visual potential (20/200 snellen equivalent or worse) and the contralateral eye must have better visual potential. * are willing and able to provide signed informed consent and willing to undertake all scheduled study-related assessments, visits, and treatments. * have received an intravitreal injection of one of the drugs listed above within 120 days of day 1 of the trial. * both males and females will be enrolled. exclusion criteria: * active intraocular inflammation or infection * history of vitreous hemorrhage within three months prior to day 1 of the study * uncontrolled ocular hypertension or glaucoma in the study eye (defined as intraocular pressure ("iop") \>25 mm hg or a cup to disc ratio \> 0.8 despite treatment with anti-glaucoma medication) or any such condition which the investigator feels may warrant a glaucoma filtering surgery during the study * history of stroke within the last three months prior to day 1 of the study * history of myocardial infarction within the last three months prior to day 1 of the study * undergone intraocular surgery or laser treatments within the last three months, * significant epiretinal membrane ("erm") or vitreomacular traction ("vmt") causing distortion of macular anatomy * no use of ocular corticosteroids within the last six months and no use of systemic corticosteroids at a dose of \>10 mg/day * not have active malignancies within the last 12 months except appropriately treated carcinoma in situ of the cervix, melanoma, and prostate cancers treated with a curative intent * inability to comply with study or follow-up procedures * women who may become pregnant or lactating or intend to become pregnant during the study * women who are of childbearing potential, including women who have had tubal ligation, must have a blood test within 21 days prior to day 1 of the study. a woman is considered to not be of childbearing potential if she is postmenopausal or has undergone hysterectomy and/or bilateral oophorectomy. postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause.

Keywords: neovascularization
prediction of serious adverse event in emergency department with dyskalemia, retrospective study

Conditions: Emergencies

Summary: dyskalemia, hypo- and hyperkalemia are common in the emergency department and are associated with increased morbidity and mortality. the potential seriousness of dyskalemia results from the potential alteration of intracardiac conduction and the increase in cardiac rhythm disorders, all associated with a lethal risk. given the aspecific symptoms of dyskalemia and the complex causal links to be acquired, it is difficult to judge the severity of the disorders in front of an initial clinical presentation of a patient in the emergency room, as the patient may present a serious condition during his stay in the emergency room, related to the dyskalemia and not prejudged at first. the ecg is recommended to judge the severity of the disorder, in association with the level of kalemia, but the electrical changes of its pattern in the context of dyskalemia are sometimes so fine that even the eye of the practitioner is not able to detect them. to date and to our knowledge, there is no tool for predicting the risk of rta or death in dyskalemia. the existing studies on the subject, including ecgs, seek to detect dyskalemia and not its complications, and the proposed tools only take into account the ecg and not the clinical context of the patient.


Eligibility criteria:
inclusion criteria: * major patient consulting in an emergency department participating in the study * who received at least a digital ecg and an ionogram in the emergency department during the study period exclusion criteria: * patient who has expressed opposition to the reuse of their data for the study

Keywords: artificial intelligence kalemia dyskalemia
exploration of management model and intervention research on fear of cancer recurrence

Conditions: Cancer Patients

Summary: 1. through cross-sectional investigation and research, construct an fear of cancer recurrence warning model to identify and screen high fear of cancer recurrencecancer populations, in order to identify predictive factors for high fear of cancer recurrence, study how cancer patients develop susceptibility to fear of cancer recurrence during the diagnosis and treatment process, including which participating factors, explore the development trajectory of fear of cancer recurrence, and effectively prevent the occurrence of high-level fear of cancer recurrence. 2. through randomized controlled trials, conduct a study on mindfulness and stress reduction psychosocial intervention for high-level fear of cancer recurrence patients, verify the effectiveness of psychosocial intervention measures targeting domestic cancer populations, and improve standardized intervention methods, intervention time, and treatment content.


Eligibility criteria:
inclusion criteria: * adults aged ≥ 18 years old * consistent with pathological diagnosis of cancer * able to understand and comply with research protocols * written informed consent can be provided * own and know how to use smart ·terminals (such as smartphones, tablets, computers, etc.) exclusion criteria: * patients with mental illness and consciousness disorders; * patients with cancer metastasis or recurrence * end of life treatment for patients.

Keywords: mindfulness-based stress reduction fear of cancer recurrence
brain-derived neurotrophic factor participates in visceral hyperalgesia in irritable bowel syndrome (ibs) patients

Conditions: Irritable Bowel Syndrome

Summary: brain-derived neurotrophic factor (bdnf), originally known to be a member of the nerve growth factor family, has aroused attention as a modulator in visceral hyperalgesia recently. visceral hypersensitivity is recognized as a clinical hallmark in ibs patients. so in this study, the investigators will focus on the role of bdnf in colonic hyperalgesia in ibs patients.


Eligibility criteria:
inclusion criteria: * patients diagnosed with irritable bowel syndrome. exclusion criteria: * patients have similar clinical symptoms as ibs, yet there is morphologic changes in the intestine.

Keywords: ibs bdnf visceral hypersensitivity
asq scores of transient hypothyroxinemia of prematurity

Conditions: Transient Hypothyroxinemia of Prematurity; Neurodevelopmental Abnormality

Summary: • transient hypothyroxinemia of prematurity (thop) is defined as free thyroxine (ft4) level is below the reference values despite normal tsh level in preterm infant. this study aims to evaluate the neurological development of infants with transient premature hypothyroxinemia (thop).


Eligibility criteria:
inclusion criteria: * newborn infants who were born at 28-36 gestational weeks * infants who were hospitalized in the neonatal intensive care unit * infants with transient hypothyroxinemia of prematurity exclusion criteria: * newborns with maternal thyroid disease, * severe intracranial issues, * chromosomal and congenital anomalies, * infants older than 36 gestational weeks
left elective colectomy in renal transplanted patients

Conditions: Left Elective Colectomy; Renal Transplanted Patients

Summary: aim of the study : to evaluate postoperative outcomes of elective left-sided colectomy in a renal transplanted population. methods : from 2010 to 2015, all consecutive patients who underwent left elective colectomy in a referral center were prospectively collected. considering our exclusion criterial, data from 120 patients were analyzed. the cohort was separated into 2 groups : renal transplanted patients (ktr-group) and non-renal transplanted patients (c-group) short and longterm outcomes were compared between the two groups. primary outcome : 90 days postoperative anastomotic leak rate

from january 2010 to december 2015, data from patients requiring an elective left colectomy for benign or malignant indication were collected prospectively in our colorectal surgery database. according to our exclusion criterial patients were retrospectively divided into two groups: kidney transplant recipients (ktr-group) and control group (c-group). the surgical indication for an oncologic left colectomy was retained by the expert surgeon, after a multidisciplinary conversation meeting comprising at least one surgeon, one gastroenterologist, one nephrologist, one radiologist and one oncologist. the surgical indication for diverticular disease was based on french guidelines. demographic, clinical, intraoperative and postoperative, histological, length of hospital stay and mortality data were collected over a 90-day period following the intervention.

Eligibility criteria:
inclusion criteria: * open or laparoscopic left elective colectomy with colo-rectal anastomosis * age \> 18 y.o. exclusion criteria: * emergency surgery * past history of rectal surgery * asa i

Keywords: benign or malign pathology renal transplanted patients anastomotic leakage
gerap's epidemiological survey on perioperative hypersensitivity reactions

Conditions: Hypersensitivity, Drug

Summary: perioperative hypersensitivity reactions are still associated with significant morbidity and mortality despite early recognition and use of epinephrine. the epidemiology of these reactions evolves over time and changes with clinical practice. the main objective is to study the epidemiology of these reactions over a 10-year period, including patient phenotype, reaction phenotype and outcome of the allergic work-up.


Eligibility criteria:
inclusion criteria: * minor and major subject * subject having experienced a perioperative hypersensitivity reaction between january the 1st 2017 and december the 31st 2027. * referred for an allegro-anesthetic workup * subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research. exclusion criteria: * subject having expressed opposition to participating in the study * inability to provide the subject with research information * subject under guardianship or guardianship * subject under safeguard of justice

Keywords: anaphylaxis perioperative hypersensitivity reactions neuromuscular blocking agents hypnotics
efficacy and safety study of egg yolk antibody in adjuvant treatment of helicobacter pylori infection

Conditions: Helicobacter Pylori Infection

Summary: helicobacter pylori is an important pathogenic factor for gastrointestinal diseases such as gastritis, peptic ulcer, gastric mucosa-associated lymphoid tissue lymphoma and gastric cancer.however, with the increasing use of antibiotics, antibiotic resistance of helicobacter pylori continues to rise. in this study, we used egg yolk antibody combined with bismuth quadruple therapy to treat patients with helicobacter pylori infection, and observed the eradication rate of helicobacter pylori, the relief of clinical symptoms and the incidence of adverse reactions.

background: helicobacter pylori is an important pathogenic factor for gastrointestinal diseases such as gastritis, peptic ulcer, gastric mucosa-associated lymphoid tissue lymphoma and gastric cancer.however, with the increasing use of antibiotics, antibiotic resistance of helicobacter pylori continues to rise. therefore, it is of great significance to explore new methodsfor the treatment of helicobacter pylori. methods: a total of 200 patients who failed to eradicate helicobacter pylori were included and randomly divided into control group and study group. the research group was treated with egg yolk antibody combined with bismuth quadruple therapy, and the research group was treated with bismuth quadruple therapy for a total of 14 days. the eradication rate of helicobacter pylori was calculated according to intention-to-treat and by-protocol analysis, and the symptom remission rate and adverse reactions were recorded during the treatment period.

Eligibility criteria:
inclusion criteria: 1. age 18 to 70 years old, male or female; 2. patients diagnosed with hp infection; 3. failure of hp eradication therapy; 4. although taking acid-suppressing drugs (ppi), the drug has been stopped for more than 2 weeks; 5. those who have not used antibiotics and (or) bismuth in the past 4 weeks; 6. understand and be willing to participate in this clinical trial and provide signed informed consent. exclusion criteria: 1. those with a history of allergy to drugs and egg yolk antibody products; 2. those with severe heart, liver, lung and kidney insufficiency; 3. those with a recent history of gastrointestinal bleeding, obstruction, perforation, tumor, and other serious organic diseases of the gastrointestinal tract; 4. those with mental illness or mental disorder that cannot be expressed normally; 5. during the research period, those who are pregnant, breastfeeding, or have a childbearing plan recently; 6. there are other persons who are not suitable for clinical trials of drugs 7. no collaborators.

Keywords: egg yolk antibody helicobacter pylori rescue therapy helicobacter pylori therapy
efficacy and safety of exenatide in the treatment of hypothalamic obesity after craniopharyngioma therapy

Conditions: Craniopharyngiomas; Hypothalamic Obesity

Summary: this hypothalamic obesity is associated with serious metabolic and psychosocial consequences. the purpose of the study is to compare the change of body weight after 6 months treatment with a lifestyle intervention + exenatide compare to the one after the same lifestyle intervention+ placebo in adults patients suffering from a hypothalamic obesity due to treatment of craniopharyngioma.

the development of glucagon-like peptide-1 (glp-1) analogues might be a solution since native glp-1 suppresses appetite and energy intake in both normal weight and obese individuals as well as in people with type 2 diabetes and delays gastric emptying. the underlying mechanisms that mediate the effects of weight involve not only central regions like the hypothalamus and the solitary tractus nucleus and area postrema but also peripheral regions as the gastrointestinal tract. these extra hypothalamic effects are of particular interest in the cases of obesity due to hypothalamic lesions. exenatide is a glucagon-like peptide-1 (glp-1) analogue with a high structural homology to human glp-1, a gut derived incretin hormone. since exenatide causes a dose-dependent weight loss, decreasing concentration of glycosylated haemoglobin as well as improving ß-cell function and systolic blood pressure, it could be an attractive treatment for both type 2 diabetes and obesity. in a double-blind placebo-controlled 24-week trial, it has been recently shown that non diabetic obese patients maintained on exenatide 10µg x 2/j lost significantly more weight than did those on placebo (5.1 kg versus 1.6).

Eligibility criteria:
inclusion criteria: * they are between 18 and 75 yrs. * they had been diagnosed with a craniopharyngioma treated by surgery and/or irradiation without sign of recurrence. * they have a bmi upper than 30kg/m² with intractable weight gain following therapy for craniopharyngioma. * they demonstrate at least one other endocrinopathy, as a marker of hypothalamic damage. * all pituitary deficiencies are correctly treated. * they gave their written, informed consent before the beginning of the study. exclusion criteria: * they have type 1 diabetes. * they have type 2 diabetes treated with insulin. * acidocetosis. * bariatric surgery * previous personal history of thyroid or pancreatic cancer. * hypercalcitoninemia. * they have been previously treated by glp1 analogs. * hypertriglyceridemia upper than 5g/l * they had previously demonstrated voluntary weight loss during the three previous months. * they are under the age of 18 years or over the age of 65 yrs. * they are maintained on medical treatment against obesity. * they are receiving supraphysiologic hydrocortisone therapy (upper than 30 mg/jour). * their gh status change during the course of the study. * exenatide is contraindicated. * psychological and/or medical problems that would create difficulties for the patient to comply with the study protocol are present.

Keywords: glucagon-like peptide-1 exenatide placebo multicenter trial